BBI Brickell Biotech, Inc.

Brickell Biotech, Inc. engages in the development of prescription therapeutics for treatment of skin diseases. Its product pipeline includes potential novel therapeutics for hyperhidrosis, cutaneous T-cell lymphoma, psoriasis, and other prevalent severe skin diseases. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO.

$0.10
As of 07/01/2022     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1999
Outstanding shares:  119,415,857
Average volume:  13,282,435
Market cap:   $15,046,398
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      
Valuation   (See tab for details)
PE ratio:   -0.29
PB ratio:   0.73
PS ratio:   43.36
Return on equity:   -248.50%
Net income %:   -11,492.51%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy